Janus Henderson Group
STRO icon

Janus Henderson Group’s Sutro Biopharma STRO Stock Holding History

Janus Henderson Group’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,005
Closed -$3.28M – 2708
2021
Q4 		$3.28M Buy
22,005
+324
+1% +$58K ﹤0.01% 1166
2021
Q3 		$4.09M Buy
21,681
+2,199
+11% +$418K ﹤0.01% 1102
2021
Q2 		$3.63M Buy
19,482
+3,235
+20% +$633K ﹤0.01% 1128
2021
Q1 		$3.7M Sell
16,247
-2,044
-11% -$485K ﹤0.01% 1062
2020
Q4 		$3.96M Buy
18,291
+2,689
+17% +$445K ﹤0.01% 1005
2020
Q3 		$1.57M Sell
15,602
-709
-4% -$67K ﹤0.01% 1094
2020
Q2 		$1.26M Sell
16,311
-514
-3% -$49.3K ﹤0.01% 1097
2020
Q1 		$1.71M Buy
16,825
+14,132
+525% +$1.49M ﹤0.01% 1020
2019
Q4 		$296K Buy
+2,693
New +$278K ﹤0.01% 1348

Other funds holding STRO

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group's STRO Position: Q1 2022 in Review

Janus Henderson Group sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 22,005 shares — an estimated $3.28M sold.

Janus Henderson Group first reported a position in STRO in Q4 2019 and held it in 9 quarters. The position peaked at $4.09M in Q3 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

  • Janus Henderson Group reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
  • Janus Henderson Group sold 22,005 Sutro Biopharma shares in Q1 2022, an estimated $3.28M.
  • Janus Henderson Group first reported a position in Sutro Biopharma in Q4 2019 and held it in 9 quarters.
  • Janus Henderson Group's Sutro Biopharma position peaked at $4.09M in Q3 2021.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Janus Henderson Group's 13F filing for Q1 2022, filed 16 May 2022.